Sign in

Private company

ACURA PHARMACEUTICALS, INC

American pharmaceutical preparations company, incorporated in New York1

In its 2023 annual report the company says: “We are an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications. We have discovered and developed three proprietary platform technologies which can be used to develop multiple products.”41 It is headquartered in Palatine, Illinois.1

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersPalatine, Illinois1
  • Incorporated inNY2
  • Business address616 N. North Court, Suite 120, Palatine, Il 600672
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

-77.7%Operating margin3
-56.2%Net margin3
-56.2%Revenue growth, 20213
-493.8%Return on equity3

Where the money goes

Where each dollar of revenue went, fiscal 2021

  • Research and development51¢$1.5M
  • Selling, general and admin42¢$1.3M
  • Interest7¢$200.0K

Out of $1.6M in revenue.3 The company lost money this year.

Financial statements

Revenue456783$1.6M in 2021−82% since 2015
0$2.5M$5.0M$7.5M$10.0M2015: $8.6M$8.6M20152016: $4.5M$4.5M2016−48%2017: $3.0M$3.0M2017−34%2018: $410.0K$410.0K2018−86%2019: $2.7M$2.7M2019+548%2020: $3.6M$3.6M2020+34%2021: $1.6M$1.6M2021−56%
Operating income456783-$1.2M in 2021−70% since 2015
-$8.0M-$6.0M-$4.0M-$2.0M02015: -$4.0M-$4.0M20152016: -$6.6M-$6.6M2016+64%2017: -$5.2M-$5.2M2017−20%2018: -$3.9M-$3.9M2018−25%2019: -$725.0K-$725.0K2019−81%2020: -$758.0K-$758.0K2020+5%2021: -$1.2M-$1.2M2021+60%
Net income456783-$879.0K in 2021−82% since 2015
-$8.0M-$6.0M-$4.0M-$2.0M02015: -$5.0M-$5.0M20152016: -$7.4M-$7.4M2016+48%2017: -$5.7M-$5.7M2017−23%2018: -$3.8M-$3.8M2018−32%2019: -$3.8M-$3.8M2019−2%2020: -$1.2M-$1.2M2020−68%2021: -$879.0K-$879.0K2021−27%
Fiscal year2015201620172018201920202021
Revenue$8.6M4$4.5M5$3.0M6$410.0K7$2.7M8$3.6M3$1.6M3
Cost of revenue
Research and development$2.6M4$4.0M5$3.7M6$1.8M7$1.5M8$1.8M3$1.5M3
Selling, general and admin$9.0M4$6.5M5$4.3M6$2.6M7$1.9M8$2.5M3$1.3M3
Operating expenses$2.8M3
Operating income-$4.0M4-$6.6M5-$5.2M6-$3.9M7-$725.0K8-$758.0K3-$1.2M3
Interest$1.2M4$893.0K5$592.0K6$223.0K7$449.0K8$450.0K3$200.0K3
Income before tax-$879.0K3
Income tax$04$05$26.6M7$07$08$03$03
Net income-$5.0M4-$7.4M5-$5.7M6-$3.8M7-$3.8M8-$1.2M3-$879.0K3
Earnings per share-$0.464-$0.625-$0.366-$0.187-$0.148-$0.043-$0.023
Earnings per share (diluted)-$0.464-$0.625-$0.366-$0.187-$0.148-$0.043-$0.023
Shares (weighted, basic)56.8M shares3
Shares (weighted, diluted)56.8M shares3

Compare ACURA PHARMACEUTICALS, INC with another company

Corporate structure

ACURA PHARMACEUTICALS, INC sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of ACURA PHARMACEUTICALS, INC

  • ACURA PHARMACEUTICALS, INC Palatine, Illinois

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What ACURA PHARMACEUTICALS, INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$2.5M3 Dec 31, 2021$2.5M3 Dec 31, 2020−0.1%
Accumulated depreciation$2.1M3 Dec 31, 2021$2.0M3 Dec 31, 2020+2.1%
Property and equipment, net$438.0K3 Dec 31, 2021$484.0K3 Dec 31, 2020−9.5%
Finance-lease assets$50.0K3 Dec 31, 2021$03 Dec 31, 2020

Intangibles and goodwill

ItemLatestA year beforeChange
Finite-lived intangibles, gross$2.0M3 Dec 31, 2021$2.0M3 Dec 31, 20200%
Accumulated amortization$1.3M3 Dec 31, 2021$1.3M3 Dec 31, 2020+2.1%
Finite-lived intangibles, net$03 Dec 31, 2021$73.0K3 Dec 31, 2020−100.0%

Leadership

Who has led ACURA PHARMACEUTICALS, INC, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Andrew D. Reddick2008–2011
  2. Robert B. Jones2011–2023

President

  1. Andrew D. Reddick2008–2011
  2. Robert B. Jones2011–2023

Chief financial officer

  1. Peter A. Clemens2007–2023

Chief operating officer

  1. Robert B. Jones2008–2010
2010201520202025
Board members and other officers (13)

Former names

  • HALSEY DRUG CO INC/NEWOct 24, 1995 to Aug 16, 20042

Timeline

  1. Oct 6, 20268-K Entered a material agreement; Completed an acquisition or sale; New debt or obligation25
  2. Aug 20, 20268-K Entered a material agreement; Completed an acquisition or sale; New debt or obligation26
  3. Jul 24, 20268-K Entered a material agreement; Completed an acquisition or sale; New debt or obligation27
  4. Jun 29, 20268-K Entered a material agreement; Completed an acquisition or sale; New debt or obligation28
  5. May 7, 20268-K Entered a material agreement; Completed an acquisition or sale; New debt or obligation29
  6. Mar 10, 20268-K Entered a material agreement; Completed an acquisition or sale; New debt or obligation30
  7. Jan 20, 20268-K Entered a material agreement; Completed an acquisition or sale; New debt or obligation31
  8. Dec 29, 20258-K Entered a material agreement; Completed an acquisition or sale; New debt or obligation32
  9. Oct 24, 20258-K Entered a material agreement; Completed an acquisition or sale; New debt or obligation33
  10. Sep 4, 20258-K Entered a material agreement; Completed an acquisition or sale; New debt or obligation34
  11. Jul 21, 20258-K Entered a material agreement; Completed an acquisition or sale; New debt or obligation35
  12. Jun 24, 20258-K Entered a material agreement; Completed an acquisition or sale; New debt or obligation36
  13. Aug 17, 2011New chief executive Robert B. Jones becomes CEO9
  14. May 23, 2008New chief executive Andrew D. Reddick becomes CEO10

Calendar

When it reported results

  1. Jun 30, 2023Reported quarterly or annual results37
  2. Nov 17, 2021Reported quarterly or annual results38

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

124 filings to the SEC since October 2021: 1 annual reports, 1 quarterly reports, 69 major events, 34 insider forms, 1 large holders, 18 other. The latest 20:

  1. Oct 6, 20268-K EDGAR
  2. Aug 26, 2026NT 10-Q EDGAR
  3. Aug 20, 20268-K EDGAR
  4. Jul 24, 20268-K EDGAR
  5. Jun 29, 20268-K EDGAR
  6. May 13, 2026NT 10-Q EDGAR
  7. May 7, 20268-K EDGAR
  8. Mar 27, 2026NT 10-K EDGAR
  9. Mar 10, 20268-K EDGAR
  10. Jan 20, 20268-K EDGAR
  11. Jan 15, 20264 OWNERSHIP DOCUMENT EDGAR
  12. Jan 15, 20264 OWNERSHIP DOCUMENT EDGAR
  13. Jan 15, 20264 OWNERSHIP DOCUMENT EDGAR
  14. Dec 29, 20258-K EDGAR
  15. Nov 21, 2025NT 10-Q EDGAR
  16. Oct 24, 20258-K EDGAR
  17. Sep 4, 20258-K EDGAR
  18. Aug 19, 2025NT 10-Q EDGAR
  19. Jul 21, 20258-K EDGAR
  20. Jun 24, 20258-K EDGAR

The 124 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$535.4K 2020–2021
Money received by yearMoney received by year, 2020–2021: $535.4K in all. PPP loans $535.4K.$0$100K$200K$300K2020 · PPP loans: $268.6K20202021 · PPP loans: $266.8K2021
Figures by year
YearPPP loansTotal
2021$266.8K$266.8K
2020$268.6K$268.6K

PPP loans

Paycheck Protection Program loans of $150,000 and up, approved April 2020 to July 2021, from the SBA40. Matched to this company by name and state.

  1. Apr 9, 2020$268.6K PPP loan (first draw) from JPMorgan Chase Bank, National Association40To ACURA PHARMACEUTICALS, INC., Palatine IL; $272.0K forgiven Jul 21, 2021
  2. Mar 12, 2021$266.8K PPP loan (second draw) from JPMorgan Chase Bank, National Association40To ACURA PHARMACEUTICALS INC., Palatine IL; $268.4K forgiven Oct 25, 2021

SEC filer profile

How ACURA PHARMACEUTICALS, INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARACURA PHARMACEUTICALS, INC1
  • CIK0000786947
  • Employer ID (EIN)11-08536401
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inNew York1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address616 N. North Court, Suite 120, Palatine, IL 600671
  • Mailing address616 N. North Court, Suite 120, ., Palatine, IL 600671
  • Phone847-705-77091
  • Shares outstanding66,001,783 as of Apr 30, 20233
  • Public float$4.9M as of Jun 30, 20213
  • On EDGAR sinceOct 24, 19951
  • Filings1,215 in all: 4 (463), 8-K (381), 10-Q (78), 3 (27), 10-K (24), NT 10-Q (22), SC 13G/A (19), DEF 14A (18)1
    All 43 form types

    SC 13D (16), 4/A (15), NT 10-K (14), SC 13D/A (14), DEFA14A (11), UPLOAD (10), 10-Q/A (9), ARS (9), CORRESP (9), S-8 (9), 10-K/A (7), CT ORDER (7), SC 13G (7), PRE 14A (6), 424B3 (3), 8-K/A (3), EFFECT (3), PRER14A (3), REGDEX (3), S-1/A (3), S-3 (3), 10-K405 (2), 424B5 (2), REGDEX/A (2), S-1 (2), S-3/A (2), 25-NSE (1), 424B2 (1), 8-A12B (1), CERTNAS (1), D (1), DEFR14A (1), PREM14A (1), RW (1), S-8 POS (1)

  • Latest filingsAnnual report (10-K) Jun 30, 2023
    Quarterly report (10-Q) Nov 15, 2021
    Proxy statement (DEF 14A) Apr 12, 2021
    Latest 8-K (8-K) Oct 6, 2026

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41